semaglutide and breast cancer GLP-1 use linked to lower incidence in large cohort study Semaglutide is Associated with Improved

B.VogelR

S.SamG.et al (2023)

As always, I encourage curious readers to look at the abstracts themselves bringing questions to your appointment is something I genuinely welcome

Regional Analysis North America United States Canada Mexico Europe United Kingdom Germany France Italy Asia-Pacific China Japan India Australia Latin America Brazil Argentina Chile Middle East and Africa South Africa Saudi Arabia UAE 8

Related Stories Moderate coffee intake may support heart health, AHA says ACC introduces cardiogenic shock designation to improve heart attack care Experts urge focus on prevention to tackle global heart failure More importantly, patients who reached a higher maximum semaglutide dose (1.7 mg or greater) during this period experienced significantly lower risks of all-cause mortality, composite cardiovascular events, cerebrovascular disease, and heart failure over the following two years than those whose maximum dose remained between 0.25 mg and 1.0 mg

However, like all medications, it comes with its own set of pros and cons